FDA PMA explained for medical device regulatory submissions
FDA PMA is premarket approval for devices subject to its requirements. See the application contents, the 180-day review and how it differs from 510(k).
FDA PMA means premarket approval, FDA's scientific and regulatory review process for evaluating the safety and effectiveness of Class III devices subject to PMA requirements. Unlike a 510(k), it requires valid scientific evidence of reasonable assurance of safety and effectiveness, not substantial equivalence to a predicate. Where the PMA requirement applies, the device needs approval before marketing. FDA's PMA overview states that distinction.
Confirm the route before you plan the PMA submission under 21 CFR Part 814. Classification comes first. The class label is not the whole answer.
Which medical devices need PMA?
PMA generally concerns Class III medical devices. But the class label alone does not settle the route. Some Class III preamendment devices may still require a Class III 510(k). If the classification regulation says that no effective date has been established for the premarket approval requirement, FDA's overview says a Class III 510(k) should be submitted. Check that regulation and the product code, and record both next to the proposed route. A plan that says only "Class III" has not made a pathway decision. FDA describes this exception in its overview.
The evidence standard needs the same care. Under 21 CFR 860.7, FDA uses valid scientific evidence to determine reasonable assurance of safety and effectiveness. Safety weighs probable benefits against probable risks under the intended conditions of use, with appropriate directions and warnings. Effectiveness concerns clinically significant results in a significant portion of the target population. Well-controlled investigations are the main evidence, though the regulation also allows other sufficient valid scientific evidence in specified circumstances, and it does not set a universal requirement for two randomized trials. Build the evidence plan around the device and the intended use, not an assumed study count.
What 21 CFR Part 814 requires in a PMA application
21 CFR 814.20 sets out PMA application contents. These cover the device, its evidence, manufacturing and administrative information. Some omissions may be justified if FDA accepts the justification. Treat the groups as a planning list for a PMA submission, not as a device-specific test checklist.
Device description and proposed labeling
Describe the device's components and operation, intended indications, alternative practices or procedures and marketing history. Include the proposed labeling and identify relevant standards, including deviations from them. The application also needs a contents list and a detailed summary. FDA may request samples. These elements are specified in section 814.20. Check that the indications in the summary, the device description and the proposed labeling match the intended use the evidence supports.
Nonclinical and clinical evidence
Include nonclinical and clinical investigations, with the applicable compliance statements. The application must also address relevant literature and favorable or adverse information. Reliance on a single investigation requires justification under section 814.20. That justification doesn't replace the evidence standard in section 860.7.
Manufacturing methods and controls
The application must describe manufacturing methods, facilities and controls. Include these details in the PMA application rather than deferring them until after approval.
Use current quality-system terms. The Quality Management System Regulation, or QMSR, took effect on February 2, 2026. It amended Part 820 and incorporated ISO 13485:2016 by reference, with applicable FDA requirements still controlling. See FDA's QMSR page.
Administrative and supporting material
The application requirements also include:
- Applicant and signature information, with an applicable US representative.
- An environmental assessment or applicable exclusion information.
- Financial certification or disclosure.
- Readily available pediatric-use information.
- Other information FDA requests.
Section 814.20 also covers incorporation by reference and updates to a pending application. It specifies an electronic format. That does not mean PMA applicants must use eSTAR. FDA's eSTAR program page lists PMA use as voluntary. Don't copy a mandatory eSTAR rule from another submission route into a PMA plan.
How FDA PMA review works
The review separates the filing decision from the assessment that leads to a regulatory action. Filing is a threshold completeness determination. It is not approval.
Under 21 CFR 814.42, FDA will notify the applicant within 45 days after receipt whether the application has been filed. If FDA accepts it for filing, the filing date is the date FDA received the application, and the 180-day review period starts on that date. Don't add 45 days to 180 days for that ordinary case. The notice window overlaps the review period.
A refusal to file changes the date. A resubmitted PMA must include the original PMA reference number. If FDA accepts that resubmission, the filing date is the date FDA receives it. The applicant may also request an informal conference, in writing, within 10 working days of receiving the refusal notice. FDA holds the conference within 10 working days of receiving the request and decides on filing within 5 working days after the conference. If FDA accepts the PMA after that conference, the filing date is the date of that decision, not the original receipt date. Section 814.42 states these rules.
FDA then conducts its in-depth review. Under 21 CFR 814.44, the actions are an approval order, an approvable letter, a not approvable letter or a denial order.
An approvable letter is not approval.
Does PMA approval take 180 days?
No. The regulations establish a 180-day review period, subject to applicable extensions, not a guarantee of approval within 180 elapsed days. Section 814.44(c) provides for action within the later of 180 days after filing or the applicable extended period.
FDA's PMA review process page explains that certain major amendments may extend review by up to 180 days. Applicant responses, further evidence and further review can make the elapsed time to final approval longer than that first period. Keep the regulatory review period separate from how long the team takes to answer FDA.
A MDUFA performance goal is not the Part 814 deadline. FDA's review-clock guidance addresses MDUFA V goals for PMAs received in fiscal years 2023 through 2027.
PMA versus 510(k)
PMA and 510(k) use different decision standards. Calling both routes "FDA approval" hides that difference. The points follow FDA's PMA overview and 510(k) overview.
| Point | PMA | 510(k) |
|---|---|---|
| Decision basis | Reasonable assurance of safety and effectiveness | Substantial equivalence to an eligible legally marketed predicate |
| Decision terminology | FDA approval | FDA clearance following a substantial-equivalence determination |
| Typical applicability | Class III devices subject to PMA requirements | Nonexempt devices for which PMA is not required, including certain Class III devices |
The different standards do not mean a 510(k) submission never needs clinical evidence. Choose the route from the device's applicable requirements, then plan the evidence for that route.
What happens after PMA approval?
PMA approval carries continuing obligations. These include approval conditions, periodic reporting commonly through annual PMA reports, Medical Device Reporting and appropriate submissions for changes affecting safety or effectiveness. FDA also requires access to relevant facilities and records. Postapproval studies apply when imposed. FDA's postapproval requirements page describes these duties.
RegAffairs AI's answer on FDA PMA provides a cited explanation of the approval pathway. Not every approval order imposes a postapproval study, and not every change needs prior supplement approval.